October 2021

November 28, 2021

Positive phase 2 data resulted in a breakthrough therapy designation for donanemab, (Eli Lilly), prompting a biologics license application submission for the agent.

November 25, 2021

In a NeurologyLive® Insights series, experts in the diagnosis and treatment of Dravet syndrome discussed the management of the disease and the utilization of approved treatments to improve outcomes in patients.

November 22, 2021

Although headache and COVID-19 have been linked together in the literature, more studies are needed to better understand the pathophysiology of these headaches and to determine the best treatment options.

October 31, 2021

Mitchell S. V. Elkind, MD, MS, MPhil, shared his perspective and offered insights into the recent updates from the American Heart Association/American Stroke Association on the landscape of stroke prevention and poststroke care.

October 30, 2021

Continued improvement in the pharmacodynamics and pharmacokinetics of S1PR modulators, particularly in modulator-receptor selectivity, should improve therapeutic efficacy while reducing the potential for AEs.

October 30, 2021

Previously, many promising treatments for PD have ultimately resulted in untenable adverse effects or in failure, but the evolving area of protein folding offers an opportunity to slow or reverse the neurodegenerative process.

October 28, 2021

Excessive daytime sleepiness is a hallmark of a number of sleep disorders, and ensuring the proper diagnosis and management of those presenting with it is crucial to care.

October 26, 2021

Years of built-up trust in the community has enabled Montefiore’s Stern Stroke Center physicians to understand more about how stroke affects multicultural communities and to break down existing barriers to care.

October 25, 2021

Proper diagnosis and effective treatment planning can drastically improve quality of life for individuals with migraine.